Direct Answer
Sermorelin is a synthetic fragment corresponding to the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29). It was formerly approved (as Geref) for diagnostic and pediatric growth-hormone-deficiency contexts and is now generally available through compounding pharmacies. Clinical evidence relates mainly to growth-hormone-deficiency settings; popular wellness and anti-aging applications are not well established.
Summary Table
Evidence Level
High
Key Information
Classification
Key Takeaways
- Sermorelin is GHRH(1-29), a growth-hormone-releasing peptide
- Mainly validated as a diagnostic test; growth hormone outperformed it for promoting growth in a head-to-head trial
- Formerly approved (Geref); now generally compounded, and anti-aging applications are not well established
Scientific Overview
In Plain English
Sermorelin is a lab-made piece of a natural hormone (GHRH) that signals the pituitary to release growth hormone. It was once an approved medicine used in children with growth-hormone deficiency and in diagnostic testing, and is now usually prepared by compounding pharmacies. Evidence is strongest in growth-hormone-deficiency settings; broader anti-aging applications are not well studied.
Scientific Details
Sermorelin is GHRH(1-29)-NH2, a growth-hormone secretagogue acting at the GHRH receptor. It is validated mainly as a diagnostic provocative test for growth-hormone deficiency. In a randomized comparison in children with growth-hormone deficiency, growth hormone (somatropin) produced significantly greater growth than GHRH(1-29), and patients developed anti-GHRH antibodies. Evidence for general wellness or anti-aging applications is limited.
How It Works
Sermorelin is described in research as a GHRH-receptor agonist; studies associate it with stimulation of pituitary growth-hormone release.
Mechanism of Action
GHRH receptor agonism
human
Studies associate sermorelin with stimulation of growth-hormone release via the GHRH receptor.
Evidence Level
Human Evidence
Sermorelin (GHRH 1-29) is validated mainly as a diagnostic provocative test for growth-hormone deficiency. In a randomized comparison in children, growth hormone (somatropin) produced significantly greater growth than sermorelin, and patients developed anti-GHRH antibodies.
Animal Evidence
Preclinical work characterized GHRH-receptor pharmacology.
Limitations
Therapeutic evidence is modest and, in a head-to-head trial, inferior to growth hormone; data for general anti-aging or wellness applications are limited, and product quality varies with compounded preparations.
References
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs.Reviewdoi:10.2165/00063030-199912020-00007 →
- A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatrica Supplement.Human Studydoi:10.1111/j.1651-2227.1993.tb12834.x →
Alternative Names
- Sermorelin acetate
- GHRH(1-29)
- GRF(1-29)
- Geref
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Several peptides discussed are research chemicals not approved for human use. Consult a licensed healthcare provider. This entry summarizes growth-hormone-deficiency literature and is not a recommendation to use sermorelin for anti-aging or wellness purposes.
This page summarizes published research and is for informational purposes only; it is not medical advice.